Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule
October 28, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis to Present at the 13th Annual BIO Investor Forum
October 03, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis Announces CUDC-907 Development Program Advancements
October 02, 2014 07:00 ET
|
Curis, Inc.
-- Expansion cohorts opened to enroll patients with relapsed/refractory Diffuse Large B-Cell Lymphoma and Multiple Myeloma --
-- Second IND open for Curis to initiate additional clinical study in...
Curis to Present at Upcoming Investor Conferences
August 27, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis Reports Second Quarter 2014 Financial Results
August 07, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis to Release Second Quarter 2014 Financial Results and Hold Conference Call on August 7, 2014
July 31, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today...
Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study of Erivedge(R) (vismodegib) in Idiopathic Pulmonary Fibrosis
June 23, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., June 23, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis to Present at the JMP Securities Healthcare Conference
June 18, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, today announced that the...
Curis Announces Re-Initiation of Patient Dosing in CUDC-427 Monotherapy Clinical Trial
June 05, 2014 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today...
Curis Announces Executive Management Transition
June 03, 2014 07:00 ET
|
Curis, Inc.
-- Ali Fattaey, Ph.D. Promoted to President and Chief Executive Officer --
-- Daniel Passeri Assumes Role of Vice Chairman, Curis Board of Directors and Strategic Advisor --
LEXINGTON, Mass.,...